|
PARP8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.03490005243634E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.516400E-01 |
| Stage1-vs-Stage3 |
7.743100E-03 |
| Stage1-vs-Stage4 |
1.94203999999143E-05 |
| Stage2-vs-Stage3 |
1.092150E-02 |
| Stage2-vs-Stage4 |
4.992100E-04 |
| Stage3-vs-Stage4 |
1.208380E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.39480041037177E-10 |
| Normal-vs-Asian |
4.41369163439731E-12 |
| Caucasian-vs-AfricanAmerican |
5.863600E-01 |
| Caucasian-vs-Asian |
2.462000E-01 |
| AfricanAmerican-vs-Asian |
7.648000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
5.557200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.91979999997205E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.882200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.086300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.911600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.024000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.296000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.820400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.47870005129391E-09 |
| Classical-VS-Follicular |
1.236270E-03 |
| Classical-VS-Other |
4.623400E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
8.50486348014101E-12 |
| Tall-VS-Other |
3.770200E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
9.703900E-03 |
| Follicular-VS-Normal |
3.22709636790819E-11 |
| Other-VS-Normal |
1.73030000327756E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.360440E-02 |
|
|
